Drug Profile


Alternative Names: VX 366

Latest Information Update: 17 Oct 2007

Price : $50

At a glance

  • Originator Childrens Hospital of Oakland
  • Class Antiarrhythmics; Butyrates; Small molecules
  • Mechanism of Action Genetic transcription stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Sickle cell anaemia; Thalassaemia

Most Recent Events

  • 06 Oct 1997 Suspended-I for Thalassaemia in Canada (PO)
  • 06 Oct 1997 Suspended-II for Thalassaemia in USA (PO)
  • 06 Oct 1997 Suspended-I for Sickle cell anaemia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top